Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

Cahn Pedro; Sax Paul E.; Squires Kathleen; Molina Jean-Michel; Ratanasuwan Winai; Rassool Mohammed; Bloch Mark; Xu Xia; Zhou Yan; Homony Brenda; Hepler Deborah; Teppler Hedy; Hanna George J.; Nguyen Bach-Yen; Greaves Wayne

首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

【24h】

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

机译：Raltegravir 1200 mg每日每日与400毫克每日两次，随着Emtricitabine和替诺福韦·富马酸核，对于先前未经处理的HIV-1感染：周96结果来自OnCemrk，随机，双盲，非流动性试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: Raltegravir 1200mg (2x600mg tablets) once daily (QD) demonstrated noninferior efficacy and similar safety to raltegravir 400mg twice daily (BID) at week 48 of the ONCEMRK trial. Here, we report the week 96 results from this study.

机译：背景：Raltegravir 1200mg（2×600mg片剂）每日一次（QD）在OnCemrk试验的第48周时每天每天两次（出价）对Raltegravir 400mg的非效力和类似的安全性。在这里，我们报告了这项研究的第96条结果。

著录项

来源
《JAIDS: Journal of acquired immune deficiency syndromes》 |2018年第5期|共10页
作者
Cahn Pedro; Sax Paul E.; Squires Kathleen; Molina Jean-Michel; Ratanasuwan Winai; Rassool Mohammed; Bloch Mark; Xu Xia; Zhou Yan; Homony Brenda; Hepler Deborah; Teppler Hedy; Hanna George J.; Nguyen Bach-Yen; Greaves Wayne;
展开▼
作者单位

Fdn Huesped Buenos Aires DF Argentina;

Harvard Med Sch Brigham &

Womens Hosp Boston MA USA;

Thomas Jefferson Univ Philadelphia PA 19107 USA;

Univ Paris Diderot Hop St Louis Paris France;

Mahidol Univ Siriraj Hosp Clin HIV Res Unit Fac Med Bangkok Thailand;

Univ Witwatersrand Helen Joseph Hosp Johannesburg South Africa;

Holdsworth House Med Practice Sydney NSW Australia;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
raltegravir; once daily; integrase inhibitor; HIV-1 infection; treatment-naive;

机译：Raltegravir;每日一次;整合酶抑制剂;HIV-1感染;治疗 - 天真;

相似文献

外文文献

1. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial [J] . Cahn Pedro, Sax Paul E., Squires Kathleen, JAIDS: Journal of acquired immune deficiency syndromes . 2018,第5期

机译：Raltegravir 1200 mg每日每日与400毫克每日两次，随着Emtricitabine和替诺福韦·富马酸核，对于先前未经处理的HIV-1感染：周96结果来自OnCemrk，随机，双盲，非流动性试验
2. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [J] . Eron Joseph J., Orkin Chloe, Cunningham Douglas, Antiviral Research . 2019,第期

机译：第9周的疗效和安全结果3阶段，随机祖母绿试验评估从增强蛋白酶抑制剂的切换加上Emtricitabine / Tenofovir Disoproxil富马酸莫霉素治疗达伦韦/钴/ Emtricitabine / Tenofovir Alafenaine的单片体方案（D / C / F / TAF）在治疗经验丰富的病毒学 - 被抑制的成年人与HIV-1一起生活
3. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial [J] . DeJesusE., RockstrohJ.K., HenryK., The Lancet . 2012,第9835期

机译：共同制定的Elvitegravir，Cobicistat，Emtricistabine和Tenofovir Disoproxil富马酸葡萄球菌与Ritonavir-Boosted Atazanavir加上共同制定的Emtricicabine和Tenofovir Disoproxil Mumarate用于初始治疗HIV-1感染：随机，双盲，第3期，非劣级试验
4. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily With Emtricitabine and Tenofovir Disoproxil Fumarate for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK a Randomized Double-Blind Noninferiority Trial [O] . Pedro Cahn, Paul E. Sax, Kathleen Squires, -1

机译：Raltegravir每日一次1200 mg vs每日两次400 mg与恩曲他滨和替诺福韦富马酸替诺福韦联用用于以前未经治疗的HIV-1感染：ONCEMRK第96周的结果一项随机双盲非劣效性试验
5. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial [O] . Pedro Cahn, Richard Kaplan, Paul E Sax, 2017

机译：Raltegravir 1200mg每日每日一次，每天两次，藤虫毒性富马酸盐和Emtrickabine，以前未经治疗的HIV-1感染：A随机，双盲，平行组，第3期，非劣级试验

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅